EmailHospital Circular 30/2008
Date Issued: 31 October 2008
Distribution: Public Hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 November 2008
We have had recent advice from the Commonwealth Government regarding changes to the Highly Specialised Drugs Program, effective 1 November 2008.
ADDED NOTE
| 9624M | Natalizumab |
Solution concentrate for IV infusion 300mg/15mL | Tysabri | BD |
NOTE:
Neurologists prescribing natalizumab under PBS listing must be registered with the Tysabri ® Australian Prescribing Program.
Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website.
Changes notified by hospital circular will be updated in the Guidelines on the Commonwealth/State Highly Specialised Drugs Program Guidelines website and the claim form amended.
Sue Race
Acting Director, Programs
Metropolitan Health & Aged Care Services
